TricDB

PDGFRB

Target Code : 320201224829
Entrez_geneID : 5159
HGNC_ID : PDGFRB
Ensembl_ID : ENSG00000113721
Chromosome : 5q32
Position : 149493400 - 149535435
Refseq Transcript : NM_002609.3
Actionable Alterations :
Population Alterations :
Alteration layout:
Functional and Clinical Implications :
PDGFRB is located on chromosome 5. The protein encoded by this gene is a cell surface tyrosine kinase receptor of a member of the platelet derived growth factor family. These growth factors are the mitogen of mesenchymal cells. The binding characteristics of growth factors to receptor monomers determine whether the functional receptors are homodimers (PDGFB or PDGFB) or heterodimers (PDGFA and PDGFB). This gene is very important for the normal development of cardiovascular system and the auxiliary function of actin cytoskeleton rearrangement. The related pathways are ERK signal and focal adhesion (adhesive plaque). GO annotations related to this gene include transferase activity, transfer of phosphorus containing groups, and protein tyrosine kinase activity. PDGFRA is an important paralog of this gene. PDGFRB is surrounded on chromosome 5 by granulocyte macrophage colony stimulating factor and macrophage colony stimulating factor receptor genes; These three genes may be related to 5-q syndrome. Translocation between chromosomes 5 and 12 fused the gene with ETV6 gene, resulting in chronic myeloproliferative disease and eosinophilia. Diseases associated with PDGFRb include KOSAKI overgrowth syndrome and penttinen premature aging syndrome (PMID: 33449152, PMID: 30607019, PMID: 2373542, PMID: 18483217, PMID: 14745969).
Therapy Interpretations :
FDA has approved the following drugs for PDGFRB targeted therapies in other tumors: Axitinib - Kidney; Dasatinib - Chronic myelogenous leukemia & Gene rearrangement positive acute lymphoblastic leukemia; Imatinib - Acute lymphoblastic leukemia & Chronic eosinophilic leukemia or eosinophilic syndrome & Chronic myeloid leukemia & Cutaneous fibrosarcoma & Gastrointestinal stromal tumor & Myelodysplastic/myeloproliferative tumor & Systemic mast cell hyperplasia; Midostaurin- Leukemia & Mast cell tumor; Nilotinib - Chronic myelogenous leukemia; Nintedanib - Lung adenocarcinoma (phase I-II acute leukemia); Pazopanib - Renal carcinoma & Soft tissue sarcoma; Ponatinib - Chronic myelogenous leukemia & Gene rearrangement positive acute lymphoblastic leukemia; Regorafenib - Colorectal cancer & Gastrointestinal stromal Tumor & Liver Cancer; Sorafenib(RAF inhibitor - Liver cancer & Kidney Cancer & Thyroid Cancer; Sunitinib - Gastrointestinal stromal tumor & Pancreatic cancer & Kidney Cancer The CFDA approved the following drugs for PDGFRB targeted therapy in other tumors: Apatinib - Gastric cancer (Phase III non-small cell lung cancer) (PMID: 26455322,PMID: 18483217, PMID: 29408302, PMID: 34023541)
Pathways and Interactions :
  • REACTOME
  • KEGG
  • NCG


Approval Notifications
Hot words
Terms of Use
Privacy Policy
biomeddb.org © 2025 Hubei University
Email: argyjbao@hotmail.com & skysky@hubu.edu.cn